Literature DB >> 19404601

[Report from NeuroUpdate in Wiesbaden (13/14 February 2009)].

M Dieterich1, G F Hamann.   

Abstract

Mesh：

Year:  2009        PMID： 19404601     DOI： 10.1007/s00115-009-2730-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  53 in total

1.  A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons.

Authors:  Anthony M Rush; Sulayman D Dib-Hajj; Shujun Liu; Theodore R Cummins; Joel A Black; Stephen G Waxman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-15       Impact factor: 11.205

2.  A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

Authors:  C Warren Olanow; Robert A Hauser; Joseph Jankovic; William Langston; Anthony Lang; Werner Poewe; Eduardo Tolosa; Fabrizio Stocchi; Eldad Melamed; Eli Eyal; Olivier Rascol
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

3.  Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.

Authors:  Megan A Cooper; Donna L Willingham; Diane E Brown; Anthony R French; Fei F Shih; Andrew J White
Journal:  Arthritis Rheum       Date:  2007-09

4.  Association between therapy outcome and right-hemispheric activation in chronic aphasia.

Authors:  Maria Richter; Wolfgang H R Miltner; Thomas Straube
Journal:  Brain       Date:  2008-03-18       Impact factor: 13.501

5.  Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.

Authors:  Cedric Manlhiot; Pascal N Tyrrell; Lisa Liang; Adelle R Atkinson; Wendy Lau; Brian M Feldman
Journal:  Pediatrics       Date:  2008-02-25       Impact factor: 7.124

6.  Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study).

Authors:  Morten Ingvar Lossius; Erik Hessen; Petter Mowinckel; Knut Stavem; Jan Erikssen; Paal Gulbrandsen; Leif Gjerstad
Journal:  Epilepsia       Date:  2007-09-19       Impact factor: 5.864

7.  Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Authors:  Alireza Minagara; T Jock Murray
Journal:  Curr Med Res Opin       Date:  2008-02-29       Impact factor: 2.580

8.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Authors:  Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree
Journal:  Arch Neurol       Date:  2008-09-08

9.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

10.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.